Nano-X director buys 60,000 shares at $0.76

Nano-X Imaging Ltd. (NNOX) director Dan S. Suesskind reported open-market purchases of a total of 60,000 Ordinary Shares on September 14, 2026, in two trades of 30,000 shares at $0.76 and 30,000 shares at $0.75 per share.

Rhea-AI Filing Summary

Nano-X Imaging Ltd. (NNOX) director Dan S. Suesskind reported open-market purchases of a total of 60,000 Ordinary Shares on September 14, 2026, in two trades of 30,000 shares at $0.76 and 30,000 shares at $0.75 per share. No Rule 10b5-1 trading plan is reported. He also continues to hold vested and unvested stock options covering 72,505 Ordinary Shares with exercise prices between $11.52 and $64.61 and expirations from 2031 to 2033, plus RSU-based Ordinary Share holdings that vest in quarterly installments through 2028.

Insider Trade Summary

Net Buyer: 60,000 shares

Net Buy 7 txns

Insider Suesskind Dan S

Role Director

Bought 60,000 shs ($45K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	30,000	$0.76	$23K
Purchase	Ordinary Shares	30,000	$0.75	$23K
holding	Stock Option (right to buy ordinary shares) F1, F4	--	--	--
holding	Stock Option (right to buy ordinary shares) F1, F5	--	--	--
holding	Stock Option (right to buy ordinary shares) F1, F6	--	--	--
holding	Ordinary Shares F1, F2	--	--	--
holding	Ordinary Shares F1, F3	--	--	--

Holdings After Transaction: Ordinary Shares — 135,336 shares (Direct); Stock Option (right to buy ordinary shares) — 72,505 contracts (Direct)

Footnotes (6)

1. F1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
2. F2. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
3. F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
4. F4. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
5. F5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.
6. F6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).

Key Figures

Shares purchased at $0.76: 30,000 shares at $0.76 per share Shares purchased at $0.75: 30,000 shares at $0.75 per share Total shares purchased: 60,000 shares +4 more

7 metrics

Shares purchased at $0.76 30,000 shares at $0.76 per share Open-market purchase on September 14, 2026

Shares purchased at $0.75 30,000 shares at $0.75 per share Open-market purchase on September 14, 2026

Total shares purchased 60,000 shares Net insider buying on September 14, 2026

Stock option exercise price $64.61 Option to buy 12,505 Ordinary Shares expiring February 9, 2031

Stock option exercise price $17.63 Option to buy 50,000 Ordinary Shares expiring December 28, 2032

Stock option exercise price $11.52 Option to buy 10,000 Ordinary Shares expiring December 31, 2033

RSU vesting schedule 12 installments of 8.33% RSUs granted December 10, 2024 and December 10, 2025 vest quarterly over three years

Key Terms

restricted share units ("RSUs"), fully vested and exercisable, exercise price

3 terms

restricted share units ("RSUs") financial

"The ordinary shares reported in this row consist of shares underlying RSUs"

fully vested and exercisable financial

"options reported in this row were granted ... and are fully vested and exercisable"

exercise price financial

"Stock Option (right to buy ordinary shares) with exercise price of 17.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NNOX director Dan S. Suesskind report?

He reported two open-market purchases of Nano-X Imaging Ordinary Shares on September 14, 2026, each for 30,000 shares, totaling 60,000 shares acquired.

At what prices were the NNOX shares purchased by the director?

Dan S. Suesskind bought 30,000 shares at $0.76 per share and another 30,000 shares at $0.75 per share, as reported for the September 14, 2026 transactions.

Were the NNOX insider share purchases made under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan, meaning the September 14, 2026 purchases were not reported as made under such a pre-arranged plan.

What stock options on NNOX does Dan S. Suesskind hold after these transactions?

He holds options over 12,505 shares at $64.61 expiring February 9, 2031, 50,000 shares at $17.63 expiring December 28, 2032, and 10,000 shares at $11.52 expiring December 31, 2033.

What RSU-based NNOX share holdings does the director have?

He has Ordinary Shares underlying RSUs granted on December 10, 2024 and December 10, 2025, which vest and settle in twelve equal quarterly installments over three years, with all underlying shares issued by December 10, 2027 and December 10, 2028, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 08:00 AM Accepted by SEC EDGAR 09/15/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Suesskind Dan S

(Last) (First) (Middle)

C/O NANO-X IMAGING LTD., OFER TECH PARK

94 SHLOMO SHMELTZER ROAD

(Street)

PETACH TIKVA 4970602

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		P		30,000	A	$0.76	80,000	D
Ordinary Shares	09/14/2026		P		30,000	A	$0.75	110,000	D
Ordinary Shares(1)								7,792(2)	D
Ordinary Shares(1)								17,544(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)(1)	$64.61							(4)	02/09/2031	Ordinary Shares	12,505		12,505	D
Stock Option (right to buy ordinary shares)(1)	$17.63							(5)	12/28/2032	Ordinary Shares	50,000		50,000	D
Stock Option (right to buy ordinary shares)(1)	$11.52							(6)	12/31/2033	Ordinary Shares	10,000		10,000	D

Explanation of Responses:

1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

2. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.

3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.

4. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.

5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.

6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Marina Gofman Feler, attorney-in-fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)